Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3943104 in Healthy and Recurrent Genital Herpes Participants
NCT05298254Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, single-blind trial of HSVTI Formulation 2 in genital herpes (13 arms), sponsored by GSK. Primary endpoints: Percentage of participants reporting each solicited administration site event at Day 29, Percentage of participants reporting each solicited systemic event at Day 29 and 6 more. Started Mar 2022; status: completed.
02
Drugs
HSVTI Formulation 2
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT05298254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298254.